Recommendations on the diagnosis and treatment of cytomegalovirus infection after stem cell transplantation;Empfehlung zur diagnostik und therapie der zytomegalievirus-infektion nach stammzell-transplantationen: Forschungsverbund komplikationen der organtransplantation durch herpesviren

Deutsche Medizinische Wochenschrift

Volumn 124, Issue 16, 1999, Pages 501-506

  Einsele, H ^a   Herbart, H ^a   Bock, T ^a   Müller, Claudia ^a   Fleckenstein, B ^b   Mach, M ^b   Stamminger, T ^b   Jahn, G ^b   Sinzger, C ^b   Koszinowski, ^c   Meyer Konig U ^d   Mertens, Th ^e   Plachter, B ^f   Reddehase, M J ^f   Schmidt, C A ^g  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e Abt fur Virologie der U   (Germany)

^f Fachbereich Med der Johannes G   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR;

CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION PREVENTION; MORTALITY; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; VIRUS INHIBITION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PROGNOSIS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033597369     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. 1 Atkinson, K., C. Arthur, K. Bradstock, B. Dale, J. Gibson, M. Golenia, J. Ho, D. Joshua, C. Juttner: Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immunesuppressed HLA-identical unrelated donor marrow transplant recipients. Bone Marr. Transplant. 16 (1995), 401-405.
2. 2 Bacigalupo, A., M. T. Van Lint, E. Tedone, F. Moro, M. A. Sauna, M. Longren, G. Trespi, F. Frassoni, D. Occhini, F. Gualandi: Early treatment of CMV infection in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marr. Transplant, 13 (1994), 753-758.
3. 3 Bass, E. B., N. R. Powe, S. N. Godman, S. L. Graziano, R. I. Griffiths, T. S. Kickler, J. R. Wingard: Efficiacy of immune globulin in preventing complications of bone marrow transplantation: A meta-analysis. Bone Marr. Transplant. 12 (1993), 273-282.
4. 4 Boeckh, M., R. A. Bowden, J. M. Goodrich, M. Pettinger, J. D. Meyers: Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 80 (1992), 1358-1364.
5. 5 Boeckh, M.,T. Gooley, P. Reusser, C. D. Bruckner, R. A. Bowden: Failure of high-dose acyclovir for prevention of CMV disease after autologous marrow transplant. J. Infect. Dis. 172 (1995), 939-943.
6. 6 Boeckh, M., T. Steven-Ayers, R. A. Bowden: Cytomegalovirus antigenemia after autologous bone marrow and peripheral blood stem cell transplantation. J. Infect. Dis. 174 (1996), 907-912.
7. 7 Boeckh, M., T. A. Gooley, D. Myerson, T. Cunningham, G. Schock, R. A. Bowden: Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88 (1996), 4063-4071.
8. 8 Boeckh, M., S. R. Riddell, T. Cunningham, D. Myerson, M. Flowers, R. A. Bowden: Increased risk of late CMV infection and disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specificT-cell responses. American Society of Hematology Thirty-eight annual meeting 1996, December 6-10, Orlando, Florida.
9. 9 Boeckh, M., G. M. Gallez-Hawkins, D. Myerson, J. A. Zaia, R. A. Bowden: Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation. Transplantation 64 (1997), 108-113.
10. 10 Bowden, R. A., S. J. Slichter, M. Sayers, D. Weisdorf, M. Cays, G. Schock, M. Banaji, R. Hacke, K. Welk, L. Fisher: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86 (1995). 3599-3603.
11. 11 Chou, S., A. Erice, M.C. Jordan, G. M. Vercellotti, K. R. Michels, C. L. Talarico, S. C. Stanat, and K. K. Biron. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. (1995) 171, 576-583.
12. 12 Einsele, H., H. Steidle, A. Vallbracht, J. G. Saal, G. Ehninger, C. A. Müller: Early occurrence of human Cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood 77 (1991), 1104-1110.
13. 13 Einsele, H., G. Ehninger, M, Steidle, A. Vallbracht, M. Müller, H. Schmidt, J. G. Saal, H. d. Waller, C. A. Müller: Polymerase chain reaction to evaluate antiviral therapy for Cytomegalovirus disease. Lancet 338 (1991), 1170-1172.
14. 14 Einsele, H., G. Ehninger, H. Hebart, P. Weber, S. Dette, H. Link, H. P. Horny, V. Meuter, S. Wagner, H. D. Waller: Incidence of local CMV infection and acute intestinal GVHD in marrow transplant recipients with severe diarrhoea. Bone Marr. Transplant. 14 (1994), 955-963.
15. 15 Einsele, H., G. Ehninger, H. Herbart, K. M. Wittkowski, U. Schuler, G. Jahn, P. Mackes, M. Herter, T. Klingebiel, J. Löffler Polymerase chain reaction monitoring reduces the incidence of Cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86 (1995), 2815-2820.
16. 16 Emmanuel, D., I. Cunningharn, K, Jules-Elysee, J. A. Brockstein, N. A. Kernan, J. Laver, D. Stover, D. A. White, A. Fels, B. Polsky, R. O'Reilly: Cytomegalovirus pneumonia after bone marrow transplantation sucessfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann. Intern. Med. 109 (1988), 777-782.
17. 17 Gerna, G., M. Furione, F. Baldanti, E. Percivalle, P. Conidi, F. Locatelli: Quantitation of human Cytomegalovirus DNA in bone marrow transplant recipients. Br. J. Haematol. 91 (1995), 674-683.
18. 18 Goodrich, J. M., M. Mori, C. A. Gleaves, C. Dumond, M. Cays, D. F. Ebeling, W. C. Buhles, B. De Armond, J. D. Meyers: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl. J. Med. 325 (1991), 1601-1607.
19. 19 Goddrich, J. M., A. Bowden, L. Fisher C. Keller, G. Schock, J. D. Mey ers: Ganciclovir prophylaxis to prevent Cytomegalovirus disease after allogeneic BMT. Ann. Intern. Med. 118 (1993), 173-178.
20. 20 Hebart, H., A. Schroeder, J. Löffler, F. klingebiel, H. Martin, B. Wassmann, F. Gerneth, H. Rabenau, G. Jahn, L. Kanz, C. A. Müller, H. Einsele: CMV-monitoring by PCR of patients undergoing autologous bone marrow and peripheral blood progenitor cell transplantation. J. Infect. Dis. 175 (1997), 1490-1493.
21. 21 Ishigaki, S., M. Takeda, T. Kura, N. Ban, T. Saitoh, S. Sakamaki, N. Watanabe, Y. Kohgo and Y. Niitsu. 1991. Cytomegalievirus DNA in the sera of patients with cytomegalievirus pneumonia. Br. J. Haematol. 79, 198-204.
22. 22 Krause, H., H. Hebart, G. Jahn, C. A. Müller, H. Einsele: Screening for CMV-specific T cell proliferation to identify patients at risk to develop late onset CMV disease. Bone Marr. Transplant. 19 (1997), 1111-1116.
23. 23 Li C. R., P. D. Greenberg, M. J. Gilbert, J. M. Goodrich, S. R. Riddell: HLA-restricted cytomegalovirus (CMV)-specificT-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83 (1994), 1971-1979.
24. 24 Ljungman, P., K. Lore, J. Aschan, S. Klaessen, I. Lewensohn-Fuchs, B. Lonnqvist, O. Ringden, J. Winiarski, A. Ehrust: Use of a semiquantitative PCR assay for cytomegalovirus DNA as a basis for preemptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marr. Transplant. 17 (1996), 583-587.
25. 25 Ljungman, P., P. Biron, A. Bosi, J. Y. Cahn, A. H. Goldstone, N. C. Gorin, H. Link, C. Messina, M. Michallet, C. Richard: Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Bone Marr. Transplant. 113 (1994), 209-212.
26. 26 Ljungman, P., D. Engelhard, H. Link, P. Birou, L. Brandt, S. Brunet, C. Cordonnier, L. Debusscher, A. de Laurenzi, H. J. Kolb: Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin. Infect. Dis. 14 (1992), 831-835.
27. 27 Prentice, H. G., E. Gluckman, R. L. Powles, P. Ljungman, N., Milpied, J. M. Fernadez Ranada, F. Mandelli, P. Kho, L. Kennedy, A. R. Bell: Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 343 (1994), 749-753.
28. 28 Reed, E. C., A. Bowden, P. S. Dandliker, K. E. Lilleby, J. D. Meyers: Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplant. Ann. Intern. Med. 109 (1988), 783-788.
29. 29 Reusser, P., S. R. Riddell, J. D. Meyers, P. D. Greenberg: Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78 (1991), 1373-1380.
30. 30 Reusser, P., R. Attenhofer, H. Hebart, C. Helg, B. Chapuis, H. Einsele: Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral stem cell or bone marrow transplants. Blood 89 (1997), 3873-3879.
31. 31 Riddell, S. R., K. S. Watanabe, J. M. Goodrich, C. R. Li, M. E. Agha, P. D. Greenberg: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell. Science 257 (1992), 238-241.
32. 32 Salzberger, B., R. A. Bowden, R. C. Hackman, C. Davis, M. Boeckh: Neutropenia in allogeneic marrow transplant recipiens receiving gancivlovir for prevention of cytomegalovirusx disease: risk factors and outcome. Blood 90 (1997), 2502-2508.
33. 33 Schmidt, C. A., H. Oettle, F. Wilborn, J. Jessen, H.Timm, R. Schwerdtfeger, J. Oertel, W. Siegert: Demonstration of cytomegalovirus after bone marrow transplantation by polymerasse chain reaction, virus culture and antigen detection in buffy coat leukocytes. Bone Marr. Transplant. 13 (1994 ), 71-75.
34. 34 Schmidt, G. M., D. A. Horac, J. C. Niland, S. R. Duncan, S. J. Forman, J. A. Zaia: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipiens of allogeneic bone marrow transplants. New Engl. J. Med. 324 (1991), 1005-1011.
35. 35 Söderberg-Naucler, C., K. N. Fish, J. A. Nelson: Reavivation of latent human Cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91 (1997), 119-126.
36. 36 Tenney, D. J., G. Yamanaka, S. M. Voss, C. W. Cianci, A. V. Tuomari, A. K, Sheaffer, M. Alam, R. J. Colonno: Lobucavir is phosphorylated in human cytomegalovirus-infected and - uninfected cells inhibits the viral DNA polymerase. Antimicrob. Agents Chemother, 41 (1997), 2680-2685.
37. 37 Walter, E. A., P. D. Greenberg, M. J. Gulbert et al: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New Engl. J. Med. 333 (1995), 1038-1044.
38. 38 Winston, D. J., G. H. Winston, K. Bartoni, C. du Mond, D. F. Ebeling, W. C. Buhles, R. E. Champlin: Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann. Intern. Med. 118 (1993), 179-184.
39. 39 Zaia, J. A., G. M. Gallez-Hawkins, B. R. Tegtmeier, A. ter Veer, X. Li, J. C. Niland, S. J. Forman: Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J. Infect, Dis. 176 (1997), 782-785.